Novel therapies in the treatment of ulcerative colitis
| Autor: | Sunanda V. Kane, Jeffrey A. Tuvlin |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Azoles
medicine.medical_specialty Chronic inflammatory disease Gastroenterology Antioxidants Adjuvants Immunologic Internal medicine Organoselenium Compounds medicine Animals Humans Pharmacology (medical) Protease Inhibitors Colitis Intensive care medicine Pharmacology Clinical Trials as Topic business.industry Probiotics Antibodies Monoclonal General Medicine Traditional therapy medicine.disease Ulcerative colitis Hormones Anti-Bacterial Agents Clinical trial Fibroblast Growth Factors Blood Component Removal Cytokines Colitis Ulcerative business Fibroblast Growth Factor 10 |
| Zdroj: | Expert opinion on investigational drugs. 12(3) |
| ISSN: | 1354-3784 |
| Popis: | Ulcerative colitis is a chronic inflammatory disease of unknown cause. Its course is one of relapse and remission and requires therapy for both the induction and maintenance of remission. The progress in the fields of genetics and immunology has afforded important advances in our understanding of the inflammatory process. Traditional therapy with non-specific anti-inflammatories for ulcerative colitis remains our gold standard as newer targeted therapies have failed to provide any improved efficacy. This review examines the most recent compounds in development for the treatment of ulcerative colitis, including data from early clinical trials and the potential clinical impact of future entities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|